Machine learning is the subset of AI that is related to the development of algorithms that can make accurate predictions of future outcomes via pattern recognition and rules-based logic. Such use of logic and algorithms can improve patient selection, provide predictive long-term outcomes, and reduce the time and cost in the execution of clinical trials.
Read the full article here.
In the latest edition of Journal of Clinical Pathways, Precision experts Chris Dillon, Chrysanthe Peteros and Larry Blandford examine the expanding role of hub support services in the pharmaceutical marketplace, emphasizing their importance as increasingly complex therapies requiring higher degrees of specialization and flexibility are launched.
In a new MedAd News feature article on the influence of value assessments, Precision Xtract’s Jacki Chou and Zac Stillerman provide their insights on the growing influence of ICER, and how manufacturers can be more proactive in shaping favorable assessments of their new treatments.
The FDA has finally released its guidance on biosimilar interchangeability. Radar on Specialty Pharmacy speaks with Ryan Cox, Precision for Value Vice President, Access Experience team on how the new guidelines reduce administrative hurdles and duplicative clinical trials. However, he notes that reimbursement issues may discourage uptake.
With the FDA’s approval of Zolgensma, the industry receives another data point in the pricing strategies for new gene therapies. As reported in Radar on Specialty Pharmacy, the two payment options offered by AveXis, makers of Zolgensma, both follow the movement to value-based purchasing. Larry Blandford, executive vice president of Precision Value and Health, discusses the rationale for and potential issues of these strategies.
Despite recent approval of the first new treatment for depression in years, most patients will still use one of the many generics on the market. As reported in Health Plan Weekly, step therapy and generics-first strategies will continue to prevail. Kellie Rademacher, Vice President, Experience and Access Team, Precision for Value, comments.
Is Real-World Evidence to be trusted? Well-documented data can make a difference to both FDA and formulary decision makers, as described by Precision for Value’s Jeremy Schafer, Senior Vice President, Access Experience and Dan Danielson, Senior Director, Access Experience, writing in Managed Healthcare Executive.
To read the full article please click here.
Increasing patient savings and reducing government spending are laudable goals. But neither the CBO nor Precision experts Jeremy Schafer, Jacki Chou, and Harry G. Schiavi believe the proposed HHS rule will work. In this Spotlight on Market Access article, they join other industry leaders in discussing the potential repercussions of the rule.
Precision for Value, Senior Vice President, Director of Value Transformation, Maureen Hennessey brings her personal experience to bear in this important Journal of Clinical Pathwaysˆ article on the social determinants of health—exploring where things stand now and opportunities for improvement.
Read the full article here.
HHS wants to eliminate drug rebates in Medicare Part D and Medicaid managed care. But the CBO projects the resulting higher premiums will cost the government dearly. In an AIS Health, Radar on Specialty Pharmacy article, Jeremy Schafer, Precision for Value Senior Vice President, Access Experience, weighs in on the potential impact of the rule, and what that means for its future. (more…)